{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chilblains/diagnosis/clinical-features/","result":{"pageContext":{"chapter":{"id":"468b6d0a-7e5f-59c0-affa-b0ee0c6eec91","slug":"clinical-features","fullItemName":"Clinical features","depth":2,"htmlHeader":"<!-- begin field c3399500-9902-4f48-9168-a90300cda85d --><h2>When should I suspect chilblains?</h2><!-- end field c3399500-9902-4f48-9168-a90300cda85d -->","summary":"","htmlStringContent":"<!-- begin item 56e99794-0389-4309-9888-a90300cda77c --><!-- begin field dd82069a-b73d-4c4a-9f70-a90300cda85d --><p><strong>Suspect chilblains in a person presenting with:</strong></p><ul><li>A history of recent (within 12-24 hours) cold exposure.</li><li>Red–purple macular, papular or nodular lesions on acral skin, most commonly the fingers and toes. The face (nose, cheeks, and earlobes) and legs (heels, lower leg, thighs and hips) can also be affected.<ul><li>Lesions may also be plaque-like or annular.</li><li>In severe cases blistering and ulceration may develop.</li></ul></li><li>Pruritus and/or burning discomfort associated with the lesions – some people may be asymptomatic.<ul><li>Lesions may be tender to palpate.</li><li>The person may not be aware of the lesions developing in the cold, but often report a persistent burning or pruritic sensation once warm.</li></ul></li></ul><p><strong>Less common presentations include:</strong></p><ul><li>Papular perniosis – small crops of chilblains on sides of fingers often on a background of <a class=\"topic-reference internal-reference\" href=\"/topics/chilblains/diagnosis/differential-diagnosis/\">acrocyanosis</a>.</li><li>Equestrian perniosis — clustered indurated, red-purple papules or plaques which may blister or ulcerate on the outer thighs (and occasionally the buttocks) of people who ride horses.<ul><li>Lesions typically appear 24-48 hours after exposure to cold and are self-limiting. Occasionally post-inflammatory hyperpigmentation, atrophy or scarring can be present after chilblains resolve.</li></ul></li><li>Severe chronic perniosis — irreversible changes including fibrosis, lymphoedema and hyperkeratosis may develop.<ul><li>Signs of severe chronic chilblains are more likely to be present when there is a background of arterial disease, prolonged cold exposure or an associated underlying condition.</li></ul></li></ul><p><strong>Chilblains tend to resolve spontaneously after 2-3 weeks — in some people they may persist throughout winter and occasionally into summer.</strong></p><ul><li>Symptoms may persist if there is continued exposure to cold, for example, associated with working conditions such as cold storage work.</li></ul><!-- end field dd82069a-b73d-4c4a-9f70-a90300cda85d --><!-- end item 56e99794-0389-4309-9888-a90300cda77c -->","topic":{"id":"98f988ea-4ee8-52e9-8212-438a79499f92","topicId":"17adddaf-c9b6-4278-9b49-932d14f56439","topicName":"Chilblains","slug":"chilblains","lastRevised":"Last revised in June 2018","chapters":[{"id":"541e07aa-8e84-55e1-817f-8d101eeb46fd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6b34a51-a690-5858-9a53-0dc5d5b0e608","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5f3bae74-0385-5bf1-b250-9e74f16cfe18","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4ae9419d-bc20-56ba-91a1-0420a339c087","slug":"changes","fullItemName":"Changes"},{"id":"e57dda70-8cbd-58d2-a2fb-8901c08e6853","slug":"update","fullItemName":"Update"}]},{"id":"ddec423e-57a6-54df-ba06-4014b41b839c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9315120c-762a-5273-867b-759b5537e4b8","slug":"goals","fullItemName":"Goals"},{"id":"666bca6f-0132-53bc-95cc-27fcbd0b4a96","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8b7e8a8e-c9dd-5555-8409-dfea005ea395","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fa795717-6d81-577e-b792-90e487b3895c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bff6f393-7347-51fa-8d46-95b80a272b9e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7da4aff5-e153-5f3f-bc51-0a943110c08d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1cc6d520-d1d7-5bcd-9d7c-b1352c82d453","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bba6260f-6b68-52b5-88c0-17f3ba449705","slug":"definition","fullItemName":"Definition"},{"id":"f4b6f42f-60f1-56db-9cc2-c9d377ec6c5a","slug":"causes","fullItemName":"Causes"},{"id":"adb617b9-5304-53c4-8f1f-6aaec8a9c35b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16008222-9ac8-5d8e-9380-55d21f8ca4d9","slug":"complications","fullItemName":"Complications"},{"id":"16a3612e-723d-580a-a4c7-157274078ba8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4c9a7bb6-deca-5726-8c77-5c4cc1bfa2a1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"468b6d0a-7e5f-59c0-affa-b0ee0c6eec91","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"08c8ac64-d612-5dfe-9926-2d0dfbc02f14","slug":"assessment","fullItemName":"Assessment"},{"id":"3db0f33f-97a0-5db2-83b8-ca9bb0e25bdc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ae9e38d9-23ba-50f8-8fd8-949711f14be6","fullItemName":"Management","slug":"management","subChapters":[{"id":"757e5e29-3beb-57b4-b55c-3050dd84bdc8","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"7f12498b-880e-5fca-908a-0c9547ba0d60","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b6be7c9c-cf67-5a2d-abb4-b8edc8d404e9","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"c98234ab-a54f-5b11-bd3d-ddc791a382d6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c4fbb70-40dc-5931-9e8e-6d8fdcd80db4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a6193060-7713-5e53-9336-66e3cb961a3a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c1d12d25-39b2-5827-a25e-dcf5536bf470","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"435de6c9-1336-5c37-8c94-8ab2ee7f2adb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"cc4fe9b8-3554-5630-88cd-6dfee9d06235","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d1b809a-3a66-5daa-a184-7cdfb748fe77","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d01450d0-bab3-5fff-9ec6-40623a484024","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4c9a7bb6-deca-5726-8c77-5c4cc1bfa2a1","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"2bd9b4e9-d1b5-56b3-883b-918169208000","slug":"basis-for-recommendation-394","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field a0451b01-8a48-4793-ba11-a90300ceb622 --><h3>Basis for recommendation</h3><!-- end field a0451b01-8a48-4793-ba11-a90300ceb622 -->","summary":null,"htmlStringContent":"<!-- begin item 3948a5d5-6ba0-4169-a43b-a90300ceafef --><!-- begin field cecdd92e-7e78-4d2d-b31a-a90300ceb622 --><p>The information on the clinical features of chilblains is based on the clinical guideline <em>Perniosis (syn. Chilblains)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">PCDS, 2015</a>] and expert opinion in Rook’s textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Bashir, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Souwer, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Cappel, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Gordon, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Dane, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">Souwer, 2017</a>].</p><!-- end field cecdd92e-7e78-4d2d-b31a-a90300ceb622 --><!-- end item 3948a5d5-6ba0-4169-a43b-a90300ceafef -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}